0001576885-24-000029.txt : 20240119 0001576885-24-000029.hdr.sgml : 20240119 20240119190742 ACCESSION NUMBER: 0001576885-24-000029 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240119 FILED AS OF DATE: 20240119 DATE AS OF CHANGE: 20240119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: OConnell Daniel Joseph CENTRAL INDEX KEY: 0001865136 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40551 FILM NUMBER: 24546785 MAIL ADDRESS: STREET 1: C/O ACUMEN PHARMACEUTICALS, INC. STREET 2: 427 PARK STREET CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Acumen Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001576885 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364108129 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 427 PARK ST. CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 BUSINESS PHONE: 925-368-8508 MAIL ADDRESS: STREET 1: 427 PARK ST. CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 4 1 wk-form4_1705709243.xml FORM 4 X0508 4 2024-01-19 0 0001576885 Acumen Pharmaceuticals, Inc. ABOS 0001865136 OConnell Daniel Joseph C/O ACUMEN PHARMACEUTICALS, INC. 427 PARK STREET CHARLOTTESVILLE VA 22902 1 1 0 0 President and CEO 1 Common Stock 2024-01-19 4 S 0 15200 3.4706 D 502485 D Represents the number of shares sold by the Reporting Person in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2023. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.3950 to $3.6500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Derek Meisner, Attorney-in-Fact 2024-01-19